GLP-1s could be a 'net positive' for ResMed shares Farrell said obesity drugs could actually become a "net positive" for ResMed, as patients with obesity tend not to engage with medical services
"In essence, there is a massive black market for it." OZEMPIC, THE HAPPY DRUG
Related Research Reading The full Retatrutide research cluster: Retatrutide Research Guide, full mechanism, trial data, reconstitution, sourcing Retatrutide Statistics 2026, quick-facts data block, cohort numbers, trial registry Phase 3 TRIUMPH Update, current trial status across the TRIUMPH programme Dosing Protocol Reference, Phase 2 escalation schedule + reconstitution maths Side Effects (Phase 2 Data), full AE profile and discontinuation breakdown Retatrutide vs Tirzepatide, triple vs dual agonist research comparison Retatrutide vs Semaglutide, triple agonist vs GLP-1 single-receptor comparison Customer Reviews Dispatched same day, impressed
Propensity score matching (1:1) was used to adjust for confounders
[119] fabricated a bilateral microneedle patch to deliver cyclodextrin-based metalorganic framework (CD-MOF)-encapsulated DXMS and paeonol to overcome the disadvantages of conventional intranasal administration, which not only enhanced the therapeutic effect of the drug but also reduced mast cell degranulation and modulated Th17/Treg cell homeostasis